The Pharmaceutical Cannabis Report: 3rd Edition Now Available to Pre-Order

Prohibition Partners are pleased to announce that The Pharmaceutical Cannabis Report: 3rd Edition is now available to pre-order, prior to publication next month.

The report, co-authored in collaboration with Cannabiscientia, gives a clear and detailed account of all activity involving cannabis and cannabinoids in the landscape of pharmaceutical medicine at a global level.

A market-sizing forecast for the global pharmaceutical cannabis industry for the period 2023–2027 is presented, with accompanying commentary, and a short analysis of the recent M&A activity and research funding activity relevant to the sector is included.

Discussion of the topics covered is informed and supported by extensive data produced during research for the report. Throughout the main sections, this data is visualised in order to provide evidence and clarification to analysis.

Whenever possible, context is provided to explain the factors that have brought about the current circumstances in the relevant sphere of activity, and what constraints face those operating within it. Recent developments and trends are highlighted in order to draw attention to the most significant dynamics in each area.

The report examines:

The report is now available to pre-order and comes with an exclusive 15% pre-sale discount. This discount also extends to the additional packages available alongside the report, including the Clinical Trials Database and Patent Portfolio (see below for more information).

There are additional data and insight packages available alongside the report, which provide specialist information, data and analysis to help connect with the industry, make smarter decisions, maximise marketing impact and improve business performance.

This is a comprehensive list of clinical trials involving cannabis and cannabinoids taking place since 2010. The total number of clinical trials contained in the dataset is 440. For each clinical trial listed, the following information is given:

This is a comprehensive review of the patent portfolios of Jazz Pharmaceuticals Ltd. (split into those held by GW Research Ltd., and those held by GW Pharmaceuticals Ltd.), and of six other leading companies involved in patenting activity for the medical application of cannabis and cannabinoids.

The dataset consists of unique patent families or “novel inventions” – meaning the same patent filed in multiple locations or at different times. The date shown is that at which the first patent in each patent family is believed to have been applied for. There are no URLs or links to the patents included in the dataset.

Key terms related to these patents were extrapolated from analysing their content, and in each case, the terms which are relevant to each individual patent family are marked. Examples of key terms include:

The total number of individual patent families analysed in the dataset is 774.

For more information and to pre-order The Pharmaceutical Cannabis Report: 3rd Edition, click here. The exclusive 15% pre-sale discount is valid until Monday 24th July. Discount is automatically applied at checkout.